Paper42877652PubMed
COVID-19 disease: novel clinical manifestations and therapeutic exploration.
Liu C and 9 others. Arch Med Sci, 2026.
Cite this record
ConductScience Library. COVID-19 disease: novel clinical manifestations and therapeutic exploration. Papers, record 42877652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42877652
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- COVID-19 disease: novel clinical manifestations and therapeutic exploration.
- Journal
- Arch Med Sci
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30831481 | The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis. | Leuk Res | 2019 | https://conductscience.org/library/papers/30831481 | PubMed |
| 2 | 31736922 | Dynamic Changes in the Microbiome and Mucosal Immune Microenvironment of the Lower Respiratory Tract by Influenza Virus Infection. | Front Microbiol | 2019 | https://conductscience.org/library/papers/31736922 | PubMed |
| 3 | 32114193 | Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. | Int J Infect Dis | 2020 | https://conductscience.org/library/papers/32114193 | PubMed |
| 4 | 32109013 | Clinical Characteristics of Coronavirus Disease 2019 in China. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32109013 | PubMed |
| 5 | 32171076 | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. | Lancet | 2020 | https://conductscience.org/library/papers/32171076 | PubMed |
| 6 | 32399094 | Statins and the COVID-19 main protease: in silico evidence on direct interaction. | Arch Med Sci | 2020 | https://conductscience.org/library/papers/32399094 | PubMed |
| 7 | 29052924 | MERS, SARS and other coronaviruses as causes of pneumonia. | Respirology | 2018 | https://conductscience.org/library/papers/29052924 | PubMed |
| 8 | 32098422 | Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. | Viruses | 2020 | https://conductscience.org/library/papers/32098422 | PubMed |
| 9 | 31110978 | Clinical Significance of Detection of Coagulation Indexes, Immune Factors and Inflammatory Factors in Patients with Pregnancy-Induced Hypertension Syndrome in China. | Iran J Public Health | 2019 | https://conductscience.org/library/papers/31110978 | PubMed |
| 10 | 32399093 | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. | Arch Med Sci | 2020 | https://conductscience.org/library/papers/32399093 | PubMed |
| 11 | 32120458 | [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. | Zhonghua Xin Xue Guan Bing Za Zhi | 2020 | https://conductscience.org/library/papers/32120458 | PubMed |
| 12 | 26847650 | Molecular mechanisms of coronavirus RNA capping and methylation. | Virol Sin | 2016 | https://conductscience.org/library/papers/26847650 | PubMed |
| 13 | 32309622 | Emerging Therapeutic Strategies for COVID-19 patients. | Discoveries (Craiova) | 2020 | https://conductscience.org/library/papers/32309622 | PubMed |
| 14 | 32187464 | A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32187464 | PubMed |
| 15 | 32125642 | Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. | Virol Sin | 2020 | https://conductscience.org/library/papers/32125642 | PubMed |
| 16 | 32100877 | Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. | J Med Virol | 2020 | https://conductscience.org/library/papers/32100877 | PubMed |
| 17 | 31978945 | A Novel Coronavirus from Patients with Pneumonia in China, 2019. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31978945 | PubMed |
| 18 | 17326933 | Review of bats and SARS. | Emerg Infect Dis | 2006 | https://conductscience.org/library/papers/17326933 | PubMed |
| 19 | 32124995 | Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. | J Med Virol | 2020 | https://conductscience.org/library/papers/32124995 | PubMed |
| 20 | 24172901 | Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. | Nature | 2013 | https://conductscience.org/library/papers/24172901 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42877652
GET https://conductscience.org/api/papers/v1/42877652/references?page=2